Use of adjuvant chemotherapy and outcomes in women age 70 and older with HER2-positive (HER2+) or triple-negative (TN) breast cancer (BC)

被引：0
|
作者：
Hsu, Tina [1 ]
Speers, Caroline [1 ]
Tyldesley, Scott [1 ]
Chia, Stephen K. L. [1 ]
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1044
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
  • [42] HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression
    Di Cosimo, Serena
    Serpico, Danila
    Porcu, Luca
    Tessari, Anna
    Molino, Leonardo
    Torri, Valter
    de Braud, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer
    Clifford A Hudis
    Nature Clinical Practice Oncology, 2006, 3 : 12 - 13
  • [44] Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients
    Johnson, Jeffrey E.
    Strassle, Paula D.
    de Oliveira, Guilherme C.
    Agala, Chris B.
    Spanheimer, Philip
    Gallagher, Kristalyn
    Ollila, David
    Muss, Hyman
    Downs-Canner, Stephanie
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 509 - 520
  • [45] Neoadjuvant therapy for triple negative and HER2-positive early breast cancer
    Harbeck, Nadia
    Gluz, Oleg
    BREAST, 2017, 34 : S99 - S103
  • [46] Recommendation of adjuvant chemotherapy and trastuzumab in older adults with HER2-positive breast cancer: A survey of oncologists
    Pal, S. K.
    Naeim, A.
    Wong, F. L.
    Chung, C. T.
    Bhatia, S.
    Mortimer, J.
    Somlo, G.
    Hurvitz, S.
    Villaluna, D.
    Hurria, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients
    Jeffrey E. Johnson
    Paula D. Strassle
    Guilherme C. de Oliveira
    Chris B. Agala
    Philip Spanheimer
    Kristalyn Gallagher
    David Ollila
    Hyman Muss
    Stephanie Downs-Canner
    Breast Cancer Research and Treatment, 2021, 189 : 509 - 520
  • [48] Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer
    Miglietta, Federica
    Dieci, Maria Vittoria
    Griguolo, Gaia
    Guarneri, Valentina
    CANCER TREATMENT REVIEWS, 2021, 98
  • [49] Alterations in HER2 status and outcome following neoadjuvant chemotherapy in HER2-positive breast cancer (BC)
    Ng, Dianna
    Krings, Gregor
    Yau, Christina
    White, Kristie
    Hou, Jie
    Chua, Anthony
    Grenert, James P.
    Chen, Yunn-Yi
    CANCER RESEARCH, 2015, 75
  • [50] Targeting triple-negative breast cancer by conversion into HER2-positive cancer: A novel therapeutic approach.
    Bernemann, Christof
    Huelsewig, Carolin
    Kiesel, Ludwig
    Liedtke, Cornelia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345